State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 2,469,425 shares of common stock in 4D Molecular Therapeutics Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 2,469,425 shares of 4D Molecular Therapeutics Inc common stock.
  • Percent of class: The filing states the shares represent 4.5% of the outstanding class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 2,416,070 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared power to dispose of 2,469,425 shares, with sole dispositive power of 0.
  • Filing entity type: State Street Corporation is identified as a parent holding company (type "HC") organized in Massachusetts.
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as the relevant subsidiaries, each classified as an investment adviser (IA).

State Street's Schedule 13G Filing on 4D Molecular Therapeutics Common Stock

State Street Corporation, headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in 4D Molecular Therapeutics Inc (CUSIP 35104E100), a biopharmaceutical company based at 5858 Horton Street, Suite 455, Emeryville, California 94608. The event triggering the filing occurred on September 30, 2026, and the statement was signed on November 9, 2026, by Alok Maheshwary, Senior Vice President of State Street Corporation.

According to the filing, State Street holds an aggregate of 2,469,425 shares beneficially owned, equating to 4.5% of the class. The company reported no sole voting power and no sole dispositive power over any of these shares. Shared voting power covers 2,416,070 shares, while shared dispositive power covers the full 2,469,425 shares. The filing notes in Item 5 that this represents ownership of 5 percent or less of the class.

The filing identifies three subsidiaries through which the position is held: SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company, all classified as investment advisers. State Street certified, as required under Item 10, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation filed a Schedule 13G reporting beneficial ownership of 2,469,425 shares, or 4.5%, of 4D Molecular Therapeutics Inc common stock as of September 30, 2026, with all voting and dispositive power held on a shared basis through three investment adviser subsidiaries.